+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Conjugate Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F- Product Image
Conjugate Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F- Product Image
New

Conjugate Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • PDF Icon

    Report

  • 184 Pages
  • February 2025
  • Region: Global
  • TechSci Research
  • ID: 5911605
Free Webex Call
10% Free customization
Description Jump to:
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

 10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The Conjugate Vaccine Market was valued at USD 19.69 Billion in 2024, and is expected to reach USD 34.10 Billion by 2030, rising at a CAGR of 9.56%. This significant market expansion is driven by the increasing recognition of preventive healthcare. Governments and healthcare organizations globally are focused on improving immunization coverage to reduce the prevalence of infectious diseases such as pneumococcal infections, Haemophilus influenzae type b (Hib), and meningococcal diseases.

Rising global healthcare spending and the prioritization of vaccination programs in both developed and developing nations have created a favorable environment for market growth. Additionally, the demand for vaccines targeting multiple pathogens in a single formulation has spurred the development of multivalent conjugate vaccines, which offer comprehensive protection while enhancing cost-effectiveness. The growing awareness of vaccines' role in preventing life-threatening diseases, particularly among vulnerable populations like infants and the elderly, has further contributed to market expansion.

Key Market Drivers

Increasing Awareness of Preventive Healthcare

The growing awareness of preventive healthcare is a crucial factor driving the expansion of the Global Conjugate Vaccine Market. In recent years, there has been a notable shift from a curative to a preventive healthcare approach. This shift is supported by the understanding that preventing diseases through vaccination is more cost-effective and less burdensome on individuals and healthcare systems than treating illnesses after they occur.

Key Market Challenges

High Manufacturing Costs

The manufacturing complexity of conjugate vaccines arises from their unique composition. These vaccines combine a weak antigen with a potent one to generate a stronger immune response. Achieving this requires advanced biotechnological techniques and strict quality control throughout production. Additionally, rigorous regulatory requirements further contribute to the overall production cost. High manufacturing costs limit the accessibility of conjugate vaccines, especially in low- and middle-income countries, where budget constraints often hinder vaccine procurement and affordability. Even in developed countries with robust healthcare systems, the high cost of conjugate vaccines can pose challenges, potentially deterring healthcare providers and individuals from prioritizing these vaccines, despite their proven efficacy.

Key Market Players

  • Sanofi S.A.
  • Pfizer Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Bharat Biotech International Limited
  • Serum Institute of India Pvt. Ltd
  • Biological E. Limited
  • Bavarian Nordic A/S
  • CSL Limited
  • Novartis AG

Report Scope

This report segments the Global Conjugate Vaccine Market by the following categories, along with detailed insights into industry trends:

By Product Type:

  • Monovalent Conjugate Vaccines
  • Multivalent Conjugate Vaccines

By Disease Indication:

  • Pneumococcal
  • Influenza
  • Meningococcal
  • Typhoid

By End-User:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

By Region:

North America:

  • United States
  • Canada
  • Mexico

Europe:

  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain

Asia-Pacific:

  • China
  • India
  • Japan
  • Australia
  • South Korea

South America:

  • Brazil
  • Argentina
  • Colombia

Middle East & Africa:

  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

The competitive landscape includes detailed profiles of the major companies operating in the Global Conjugate Vaccine Market.

Available Customizations

TechSci Research offers customizations for the Global Conjugate Vaccine Market report to suit specific business needs. Customization options include:

  • Detailed analysis and profiling of up to five additional market players.

This product will be delivered within 1-3 business days.

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Global Conjugate Vaccine Market Outlook
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Product Type (Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine)
4.2.2. By Disease Indication (Pneumococcal, Influenza, Meningococcal, Typhoid)
4.2.3. By End-User (Hospitals & Clinics, Ambulatory care Centers, Others)
4.2.4. By Region
4.2.5. By Company (2024)
4.3. Market Map
4.3.1. By Product Type
4.3.2. By Disease Indication
4.3.3. By End-User
4.3.4. By Region
5. Asia Pacific Conjugate Vaccine Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product Type
5.2.2. By Disease Indication
5.2.3. By End-User
5.2.4. By Country
5.3. Asia Pacific: Country Analysis
5.3.1. China Conjugate Vaccine Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Product Type
5.3.1.2.2. By Disease Indication
5.3.1.2.3. By End-User
5.3.2. India Conjugate Vaccine Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Product Type
5.3.2.2.2. By Disease Indication
5.3.2.2.3. By End-User
5.3.3. Australia Conjugate Vaccine Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Product Type
5.3.3.2.2. By Disease Indication
5.3.3.2.3. By End-User
5.3.4. Japan Conjugate Vaccine Market Outlook
5.3.4.1. Market Size & Forecast
5.3.4.1.1. By Value
5.3.4.2. Market Share & Forecast
5.3.4.2.1. By Product Type
5.3.4.2.2. By Disease Indication
5.3.4.2.3. By End-User
5.3.5. South Korea Conjugate Vaccine Market Outlook
5.3.5.1. Market Size & Forecast
5.3.5.1.1. By Value
5.3.5.2. Market Share & Forecast
5.3.5.2.1. By Product Type
5.3.5.2.2. By Disease Indication
5.3.5.2.3. By End-User
6. Europe Conjugate Vaccine Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product Type
6.2.2. By Disease Indication
6.2.3. By End-User
6.2.4. By Country
6.3. Europe: Country Analysis
6.3.1. France Conjugate Vaccine Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product Type
6.3.1.2.2. By Disease Indication
6.3.1.2.3. By End-User
6.3.2. Germany Conjugate Vaccine Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product Type
6.3.2.2.2. By Disease Indication
6.3.2.2.3. By End-User
6.3.3. Spain Conjugate Vaccine Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product Type
6.3.3.2.2. By Disease Indication
6.3.3.2.3. By End-User
6.3.4. Italy Conjugate Vaccine Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Product Type
6.3.4.2.2. By Disease Indication
6.3.4.2.3. By End-User
6.3.5. United Kingdom Conjugate Vaccine Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Product Type
6.3.5.2.2. By Disease Indication
6.3.5.2.3. By End-User
7. North America Conjugate Vaccine Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product Type
7.2.2. By Disease Indication
7.2.3. By End-User
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States Conjugate Vaccine Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product Type
7.3.1.2.2. By Disease Indication
7.3.1.2.3. By End-User
7.3.2. Mexico Conjugate Vaccine Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product Type
7.3.2.2.2. By Disease Indication
7.3.2.2.3. By End-User
7.3.3. Canada Conjugate Vaccine Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product Type
7.3.3.2.2. By Disease Indication
7.3.3.2.3. By End-User
8. South America Conjugate Vaccine Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product Type
8.2.2. By Disease Indication
8.2.3. By End-User
8.2.4. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Conjugate Vaccine Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product Type
8.3.1.2.2. By Disease Indication
8.3.1.2.3. By End-User
8.3.2. Argentina Conjugate Vaccine Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product Type
8.3.2.2.2. By Disease Indication
8.3.2.2.3. By End-User
8.3.3. Colombia Conjugate Vaccine Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product Type
8.3.3.2.2. By Disease Indication
8.3.3.2.3. By End-User
9. Middle East and Africa Conjugate Vaccine Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product Type
9.2.2. By Disease Indication
9.2.3. By End-User
9.2.4. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa Conjugate Vaccine Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product Type
9.3.1.2.2. By Disease Indication
9.3.1.2.3. By End-User
9.3.2. Saudi Arabia Conjugate Vaccine Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product Type
9.3.2.2.2. By Disease Indication
9.3.2.2.3. By End-User
9.3.3. UAE Conjugate Vaccine Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product Type
9.3.3.2.2. By Disease Indication
9.3.3.2.3. By End-User
9.3.4. Egypt Conjugate Vaccine Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Product Type
9.3.4.2.2. By Disease Indication
9.3.4.2.3. By End-User
10. Market Dynamics
10.1. Drivers
10.2. Challenges
11. Market Trends & Developments
11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions
12. Global Conjugate Vaccine Market: SWOT Analysis
13. Porter’s Five Forces Analysis
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Product
14. Competitive Landscape
14.1. Sanofi S.A
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Products & Services
14.1.4. Current Capacity Analysis
14.1.5. Financials (In case of listed)
14.1.6. Recent Developments
14.1.7. SWOT Analysis
14.2. Pfizer Inc.
14.3. Merck & Co. Inc.
14.4. GlaxoSmithKline plc
14.5. Bharat Biotech International Limited
14.6. Serum Institute of India Pvt. Ltd
14.7. Biological E. Limited
14.8. Bavarian Nordic A/S
14.9. CSL Limited
14.10. Novartis AG
15. Strategic Recommendations16. About the Publisher & Disclaimer

Companies Mentioned

  • Sanofi S.A
  • Pfizer Inc.
  • Merck & Co. Inc.
  • GlaxoSmithKline plc
  • Bharat Biotech International Limited
  • Serum Institute of India Pvt. Ltd
  • Biological E. Limited
  • Bavarian Nordic A/S
  • CSL Limited
  • Novartis AG

Table Information

Report AttributeDetails
No. of Pages184
PublishedFebruary 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 19.69 Billion
Forecasted Market Value ( USD ) by 2030 $ 34.1 Billion
Compound Annual Growth Rate9.5%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Conjugate Vaccine Market Size, Share & Trends Analysis Report By Product (Monovalent, Multivalent), By Brand (Prevnar, CAPVAXIVE), By Disease, By Pathogen, By Patient, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Conjugate Vaccine Market Size, Share & Trends Analysis Report By Product (Monovalent, Multivalent), By Brand (Prevnar, CAPVAXIVE), By Disease, By Pathogen, By Patient, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 150 Pages
  • Global
From
Conjugate Vaccine Market by Type, Indication, Pathogen Type, End-User - Global Forecast 2025-2030 - Product Image

Conjugate Vaccine Market by Type, Indication, Pathogen Type, End-User - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Conjugate Vaccines - Global Strategic Business Report - Product Image

Conjugate Vaccines - Global Strategic Business Report

  • Report
  • 271 Pages
  • Global
From
Conjugate Vaccine Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Conjugate Vaccine Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 86 Pages
  • Global
From
2025 Global Forecast for Conjugate Vaccine Market (2026-2031 Outlook)-High Tech Outlook Report - Product Image

2025 Global Forecast for Conjugate Vaccine Market (2026-2031 Outlook)-High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.